Generic semaglutide: what tentative approval means
There is no generic semaglutide you can buy yet. On April 7, 2026, the FDA gave Apotex a tentative approval for a generic version of the Ozempic pen, which means the FDA judged it ready but cannot let it be sold until patents or exclusivity on the brand are resolved. The Orange Book lists a patent on the semaglutide molecule running to December 5, 2031. Today your choices are the brand, from $149 a month for the Wegovy pill on NovoCare's self-pay price list, or compounded semaglutide from $59 a month at the telehealth companies we compared.
What this comes down to
- Apotex holds the only generic semaglutide application in the FDA's database, and its status is tentative approval: the FDA does not allow a tentatively approved generic to be marketed.
- The three Apotex strengths match three Ozempic pens. Nothing in the FDA's records describes a generic Wegovy or a generic pill.
- The Orange Book lists the patent on semaglutide itself with an expiration date of December 5, 2031. Court cases or settlements can move a launch date; the FDA's listing does not predict one.
- Today: brand Wegovy pens are $349 a month at NovoCare's self-pay price, and compounded semaglutide runs $59 to $299 a month at the companies below.
- Compounded, lowest$59
- Wegovy pill 1.5 mg, NovoCare$149
- Compounded, half charge this or less$190
- Wegovy pen, NovoCare$349
- Ozempic pen 2 mg, NovoCare$499
Regular monthly prices, before any first-month offer; compounded prices exclude membership fees.
Is there a generic semaglutide yet?
Not one you can buy. The FDA's drug database lists one generic application for semaglutide, Apotex's ANDA 220314, and its status is "None (Tentative Approval)", dated April 7, 2026. It covers three injection strengths, 2 mg/3 mL, 4 mg/3 mL, 8 mg/3 mL, the same strengths as three Ozempic pens[1]. Every other semaglutide product in the database is Novo Nordisk's own: Ozempic, Wegovy, Wegovy HD, Rybelsus and the Wegovy and Ozempic tablets.
| Application | Holder | Products | Status |
|---|---|---|---|
| NDA 209637 | Novo Nordisk | Ozempic pens | Approved, sold |
| NDA 215256 | Novo Nordisk | Wegovy and Wegovy HD pens | Approved, sold |
| NDA 213051, 213182, 218316 | Novo Nordisk | Rybelsus, Ozempic and Wegovy tablets | Approved, sold |
| ANDA 220314 | Apotex | Generic semaglutide injection, three strengths | Tentative approval, not sold |
Semaglutide applications in Drugs@FDA (read October 2026)
What does a tentative approval mean?
“If a generic drug product is ready for approval before the expiration of any patents or exclusivities accorded to the reference listed drug product, FDA issues a tentative approval letter to the applicant. … FDA delays final approval of the generic drug product until all patent or exclusivity issues have been resolved. A tentative approval does not allow the applicant to market the generic drug product.”
[2]
In plain terms: the FDA has reviewed the science and found nothing blocking approval, but legal protections on the brand still stand in the way. Until the FDA grants final approval, no pharmacy can stock Apotex's semaglutide.
When could generic semaglutide reach pharmacies?
The FDA's Orange Book lists the patents and exclusivities on each brand. For the Ozempic pens that match Apotex's strengths, it lists a patent claiming the semaglutide molecule and its product, number 8,129,343, expiring December 5, 2031. Most of Ozempic's other listed patents cover the product rather than the molecule and carry a request to delist them, and the latest-dated ones cover particular uses rather than the molecule. Ozempic also has an exclusivity for a newer approved use that runs to January 28, 2028[3]. Wegovy carries the same molecule patent to the same date[4].
Generic companies can challenge patents in court, and brand and generic makers sometimes settle on an earlier entry date. The Orange Book records what the brand's maker listed, not when a generic will launch. Treat any article that names a launch date as a guess unless it cites a court ruling or a settlement.
Generic vs compounded vs brand semaglutide: what is the difference?
| FDA review | Can you buy it now? | Where | |
|---|---|---|---|
| Brand (Ozempic, Wegovy) | Approved | Yes | Retail pharmacies, NovoCare, some telehealth companies |
| Generic (Apotex) | Tentatively approved | No | Not sold until final approval |
| Compounded | Not FDA-approved | Yes, on a prescription | Telehealth companies, through compounding pharmacies |
Three kinds of semaglutide
A generic must show it matches the brand and goes through FDA review; a compounded drug does not, and the FDA does not check its safety, effectiveness or quality before it is sold[5]. Compounded versus brand covers what that difference means for you, and the FDA status of compounded semaglutide covers the rules pharmacies work under since the shortage ended.
What does semaglutide cost today without a generic?
On NovoCare's self-pay price list, the Wegovy pill starts at $149 a month for the 1.5 mg dose, and the Wegovy pen is $349 a month after a $199 rate for new patients' first two fills. Ozempic pens are $349 a month up to the 1 mg dose and $499 for 2 mg. Wegovy cost without insurance has every dose.
Compounded semaglutide at the telehealth companies below costs $59 to $299 a month for the medication, and at least half of them charge $190 or less. The lowest, at Collective, is $59 a month plus a $199 yearly membership.
| Company | Medication a month | Membership |
|---|---|---|
| Collective | $59 | $199 a year |
| CoreAge Rx | $99 | None listed |
| Eden | $99 | None listed |
| SnagRx | $99 | None listed |
| YourEra | $143.20 | None listed |
| Sprout Health | $149 | None listed |
| bmiMD | $159 | None listed |
| Trimi | $175 | None listed |
| Gala Health | $179 | None listed |
| Oak | $190 | None listed |
| Luvo Health | $209 | None listed |
| Wellorithm | $247 | None listed |
| Enhance MD | $249 | None listed |
| RxSpan MD | $249 | None listed |
| Bodybuilding Health+ | $279 | None listed |
| Found | $289 | None listed |
| Direct Meds | $297 | None listed |
| MEDGm | $299 | None listed |
| Willow | $299 | None listed |
Compounded semaglutide, month to month, at telehealth companies we review (read September 2026 to October 2026)
Read the review before you buy: Collective, CoreAge Rx, Eden, SnagRx, YourEra, and Sprout Health are the lowest month-to-month prices on the list. How to check a compounding pharmacy is worth five minutes before your first order.
Questions people actually ask
Is generic semaglutide available in the US?
Not yet. Apotex received a tentative approval for a generic semaglutide injection on April 7, 2026, and a tentative approval does not allow the company to sell it. No other generic semaglutide application appears in the FDA's database.
When will generic Ozempic be available?
No date is set. The FDA's Orange Book lists the patent on the semaglutide molecule through December 5, 2031, but court cases or settlements can change when a generic actually launches.
Is compounded semaglutide the same as generic semaglutide?
No. A generic is reviewed by the FDA and must match the brand. A compounded drug is made by a pharmacy for a prescription and is not FDA-approved, which means the FDA does not check it before it is sold.
Is there a generic Wegovy?
No. The only generic semaglutide application in the FDA's database matches three Ozempic pen strengths, and it has only tentative approval. Wegovy has its own patents and exclusivities listed in the Orange Book.
What is the cheapest semaglutide without insurance?
Among the options you can buy now, compounded semaglutide at telehealth companies starts at $59 a month for the medication. The brand Wegovy pill starts at $149 a month on NovoCare's self-pay price list.
Sources
Every source below was read for this article, with the claim it supports written beside it.
- 1.Drugs@FDA: ANDA 220314, Apotex Inc., semaglutide injection. U.S. Food and Drug Administration, 2026. SourceANDA 220314 (Apotex Inc.) covers semaglutide injection 2 mg/3 mL, 4 mg/3 mL and 8 mg/3 mL, each with marketing status "None (Tentative Approval)"; openFDA records the original submission's status as tentative approval dated April 7, 2026. A search of every application by active ingredient returned NDAs 209637, 213051, 213182, 215256 and 218316 and this ANDA only.
- 2.Drugs@FDA Glossary of Terms. U.S. Food and Drug Administration, 2017. Source · Document dated November 2017Defines tentative approval: FDA issues it when a generic is ready for approval before the brand's patents or exclusivities expire, delays final approval until those issues are resolved, and a tentative approval does not allow the applicant to market the generic.
- 3.Orange Book: Patent and Exclusivity for N209637 (Ozempic). U.S. Food and Drug Administration, 2026. SourceFor Ozempic products 001, 002 and 003, patent 8,129,343 is listed as a drug substance and drug product patent expiring 12/05/2031; most device patents carry a delist request; the latest listed patents are method-of-use patents; exclusivity I-961 expires 01/28/2028.
- 4.Orange Book: Patent and Exclusivity for N215256 (Wegovy). U.S. Food and Drug Administration, 2026. SourceWegovy product 001 lists patent 8,129,343 (drug substance and drug product) expiring 12/05/2031, with exclusivities I-935 to 03/08/2027 and I-973 to 08/15/2028.
- 5.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Compounded drugs are not FDA-approved; the FDA does not verify their safety, effectiveness or quality before they are marketed.
Key figures